//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...









Loading...
The Lancet Infectious Diseases is the leading clinical infectious diseases journal for peer-reviewed research and review, comment, and news. 🌐 https://www.thelancet.com/journals/laninf/home
The Lancet Infectious Diseases
Behind every paper at The Lancet Group are layers of editorial scrutiny and integrity checks. ✅ Learn how we work with authors and teams around the world to support trustworthy research: spkl.io/6332576U3b
New research Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial www.thelancet.com/journals/lan...
New Correspondence Estimation of the Ebola outbreak size in the Democratic Republic of the Congo www.thelancet.com/journals/lan...
New Research Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia www.thelancet.com/journals/lan...
New Research Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial www.thelancet.com/journals/lan...
New research article Widespread circulation of #Alongshan virus in Austria and serological evidence for infection in humans: a nationwide molecular and serological observational study www.thelancet.com/journals/lan... #IDSky #ClinMicro #ViroSky #flavivirus #OpenAccess #OA
News Piece Update on the Ebola virus outbreak in DR Congo www.thelancet.com/journals/lan...
8d
21h
New comment Can better oral care reduce non-ventilator hospital-acquired pneumonia? www.thelancet.com/journals/lan...
2d
4d
9d
New Online! A timely Correspondence on the potential under-detection of clinically significant #hantavirus cases in #Argentina. Authors estimate 292 clinically significant cases under the baseline scenario, compared with 90 officially reported. www.thelancet.com/journals/lan...
3d
21h
4d
4d
The ongoing outbreak of Bundibugyo virus disease, a form of Ebola virus disease caused by the Bundibugyo virus, in the Democratic Republic of the Congo is evolving rapidly. As of May 27, 2026, 1031 su...
www.thelancet.com
Estimation of the Ebola outbreak size in the Democratic Republic of the Congo
Update on the Ebola virus outbreak in DR Congo
As of June 8, 2026, authorities in DR Congo are struggling to contain an outbreak of Ebola virus disease due to Bundibugyo virus, with 598 confirmed cases and 115 deaths. Talha Burki reports.
www.thelancet.com
The Lancet Infectious Diseases
The Lancet
The Lancet Infectious Diseases
The Lancet Infectious Diseases
The Lancet Infectious Diseases
The Lancet Infectious Diseases
The Lancet Microbe
The Lancet Infectious Diseases
✨ NEW EPISODE ✨ #ScienceInContext This week Dr @eonore.bsky.social speaks with Dr Ruth McCabe about the current #Ebola outbreak & collaboration with @who.int & regional health authorities estimating the outbreak size published in @thelancetinfdis.bsky.social - one to watch! youtu.be/x-V6lYG7HvE
The Lancet Reg Health-Europe
2d
youtu.be
MRC Centre for Global Infectious Disease Analysis
This multicentre randomised controlled trial demonstrates that improving oral care reduces NV-HAP incidence among hospitalised patients, compared with usual care. Our findings provide novel and clinic...
www.thelancet.com
Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia
In both VACV-naive and VACV-experienced participants, BNT166a was well tolerated, with local and systemic reactogenicity events occurring more frequently after the second dose than the first. BNT166a ...
www.thelancet.com
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial
Yellow fever booster vaccination was safe and immunogenic in healthy Gambian children. Protective neutralising antibody waned following primary vaccination and boosting had a more pronounced effect in...
www.thelancet.com
www.thelancet.com
Non-ventilator hospital-acquired pneumonia (NV-HAP) is the most frequent and deadly health-care-associated infection.1,2 The Hospital Acquired Pneumonia Prevention (HAPPEN) trial, presented by Nicole ...
Can better oral care reduce non-ventilator hospital-acquired pneumonia?